The molecule which can inhibits activity of the protein related to pancreatic cancer

Early diagnosis of pancreatic cancer is difficult and lacks specific drugs. Recently, according to research through recombinant horse proteins, researchers from France and Spain have found a substance that has been used to treat anxiety can interfere with the development of pancreatic cancer.

Pancreatic cancer is one of the deadliest tumors. At present, it is generally treated through chemotherapy program. Nupr1 protein belongs to the "intrinsic disorder protein". As early as the 20th century, 90 scientists have pointed out that it is involved in the development of pancreatic cancer. Now, scientists have discovered molecules that can inhibit the activity of this protein.

Experts have shown that this study has been selected from among more than 1,000 drugs that have been approved for the treatment of various diseases to screen for the effective inhibition of Nupr1 activity. Through the combination of computer simulation and pharmacological test, it can be seen that this molecule can interact with Nupr1 protein. In-vitro experiments show that it can reduce the ability of tumor cells to activate and transfer and completely inhibit the possibility of colony formation. The active compound has been tested for efficacy in animals and has been shown to prevent the development of the disease. This compound is trifluoperazine.

Trifluoperazine was previously used only as an antipsychotic in clinical practice, demonstrating its excellent anti-tumor effect. The study has a new shift in the direction of treatment of pancreatic cancer. Inhibition of Nupr1 may become a new treatment device for the treatment of the pancreatic cancer. By the way, Flarebio provides you with recombinant proteins of good quality like recombinant CDH2.